Data availability
All serological data are included in the manuscript. Additional clinical data is available upon reasonable request.
Acknowledgments:
This work was supported by institutional funds from the University of Pennsylvania and an NIH grant AI082630 (to E.J.W.). We thank Jeffrey Lurie and we thank Joel Embiid, Josh Harris, David Blitzer for philanthropic support. E.J.W. is supported by the Parker Institute for Cancer Immunotherapy which supports the cancer immunology program at UPenn. We thank all members of the Wherry Lab and the Penn COVID-19 Sample Processing Unit for sample procurement, processing and logistics. We thank the staff of the Penn Medicine Biobank. We thank Florian Krammer (Mt. Sinai) for sending us the SARS-CoV-2 spike RBD expression plasmids within hours of requesting this material.
Author Contributions:
DDF conceptualized and designed the study, collected data, drafted the initial manuscript, and revised the manuscript.
SG led the serological experiments, collected data, and revised the manuscript.
SM conceptualized and designed the study, designed the data collection instruments, carried out the analyses, and revised the manuscript.
MBD designed the data collection instruments, collected data, carried out the analyses, and revised the manuscript.
MRP collected data and revised the manuscript.
ECW collected data and revised the manuscript.
JSG conceptualized and designed the study, and revised the manuscript.
CPA completed serological assays, analyzed data, and revised the manuscript.
MJB completed serological assays, analyzed data, and revised the manuscript.
MW completed serological assays, analyzed data, and revised the manuscript.
ECG completed serological assays, analyzed data, and revised the manuscript.
EMA completed serological assays, analyzed data, and revised the manuscript.
ARG obtained and proceeded samples from recovered donors.
JK obtained and proceeded samples from recovered donors.
NH obtained and proceeded samples from recovered donors.
AP obtained and proceeded samples from recovered donors.
JD obtained and proceeded samples from recovered donors.
OK designed and established recovered donor cohort.
DM processed and characterized samples from recovered donors.
AB oversaw acquisition, processing, and characterization of samples from recovered donors.
LAV designed and established recovered donor cohort.
JW supervised recruitment of participants in PMBB and identification of samples for serology testing.
AV analyzed demographic data of PMBB participants.
RL provided samples for the pre-pandemic pregnant controls.
JSM provided statistical advice, performed statistical analyses, and revised the paper.
DJR provided input on the use of PMBB controls and revised the manuscript.
MAE provided input and samples for the pre-pandemic pregnant controls and revised the manuscript.
EJW designed, established, and oversaw healthy donor cohort studies and made revisions to the manuscript.
KMP conceptualized and designed the study, coordinated and supervised data collection, and revised the manuscript
SEH conceptualized and designed the study, coordinated and supervised serological studies, and revised the manuscript.
Competing interests:
SEH has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. EJW is a member of the Parker Institute for Cancer Immunotherapy. EJW has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. EJW is a founder of Surface Oncology and Arsenal Biosciences. EJW has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. All other authors declare no competing interests related to this work.
Additonal information: Correspondence and requests for materials should be addressed to [email protected] and [email protected]. Reprints and permissions information is available at www.nature.com/reprints.